L
Lawrence D. True
Researcher at University of Washington
Publications - 321
Citations - 34128
Lawrence D. True is an academic researcher from University of Washington. The author has contributed to research in topics: Prostate cancer & Prostate. The author has an hindex of 72, co-authored 289 publications receiving 29134 citations. Previous affiliations of Lawrence D. True include United States Department of Veterans Affairs & Emory University.
Papers
More filters
Journal ArticleDOI
I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.
Andrew Herstein,Kent E. Wallner,Gregory Merrick,Hiroki Mitsuyama,Julius Armstrong,Lawrence D. True,William Cavanagh,Wayne M. Butler +7 more
TL;DR: Patients treated with Pd-103 had more intense radiation prostatitis in the first month after implantation, but they recovered from their radiation-related symptoms sooner than I-125 patients, consistent with palladium's shorter half-life.
Journal Article
Prostate Short-Chain Dehydrogenase Reductase 1 (PSDR1): A New Member of the Short-Chain Steroid Dehydrogenase/Reductase Family Highly Expressed in Normal and Neoplastic Prostate Epithelium
Biaoyang Lin,James T. White,Camari Ferguson,Shunyou Wang,Robert L. Vessella,Roger Bumgarner,Lawrence D. True,Leroy Hood,Peter S. Nelson +8 more
TL;DR: A novel gene that is designated prostate short-chain dehydrogenase/reductase 1 (PSDR1), that exhibits increased expression on exposure to androgens in the LNCaP prostate cancer cell line is identified.
Journal ArticleDOI
Multicolor multicycle molecular profiling with quantum dots for single-cell analysis.
TL;DR: This protocol, using a self-assembly between protein A–decorated universal quantum dots and intact primary antibodies, offers a fast, simple and purification-free route for an on-demand preparation of antibody-functionalized quantum dot libraries.
Journal ArticleDOI
Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study.
Mary-Ellen Taplin,Robert B. Montgomery,Christopher J. Logothetis,Glenn J. Bubley,Jerome P. Richie,Bruce L. Dalkin,Martin G. Sanda,Massimo Loda,Lawrence D. True,Patricia Troncoso,Elizabeth M. Genega,Steven P. Balk,Peter S. Nelson,Wanling Xie,Christopher M. Haqq,Namphuong Tran,Cameron S. Liu,Thian Kheoh,Arturo Molina,Philip W. Kantoff +19 more
TL;DR: Results confirmed that LHRPC is infrequently cured with prostatectomy and neoadjuvant androgen deprivation therapy (ADT) has not improved outcomes and residual intra-prostatic androgens remain.
Journal ArticleDOI
Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration
Franck Bladou,Robert L. Vessella,Kent R. Buhler,William J. Ellis,Lawrence D. True,Paul H. Lange +5 more
TL;DR: Castration‐induced effects in LuCaP 23.1 tumors were characterized by an increase in number of apoptotic cells and a decrease in proliferative activity, and the androgen‐independent tumor relapse after castration was associated with a low apoptotic index with no increase in proliferatives activity.